Relay Therapeutics, Inc.
NASDAQ:RLAY
6.14 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 25.546 | 1.381 | 3.029 | 82.654 | 0 | 0 |
| Cost of Revenue
| 5.269 | 4.13 | 3.925 | 3.549 | 2.845 | 2.154 |
| Gross Profit
| 20.277 | -2.749 | -0.896 | 79.105 | -2.845 | -2.154 |
| Gross Profit Ratio
| 0.794 | -1.991 | -0.296 | 0.957 | 0 | 0 |
| Reseach & Development Expenses
| 330.018 | 246.355 | 172.65 | 99.862 | 70.306 | 41.034 |
| General & Administrative Expenses
| 74.95 | 65.978 | 57.386 | 38.588 | 13.742 | 8.855 |
| Selling & Marketing Expenses
| 4.245 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 74.95 | 65.978 | 57.386 | 38.588 | 13.742 | 8.855 |
| Other Expenses
| -0.018 | -0.02 | -0.004 | -0.016 | -0.058 | -0.009 |
| Operating Expenses
| 404.968 | 312.333 | 230.036 | 138.45 | 84.048 | 49.889 |
| Operating Income
| -373 | -299.275 | -364.698 | -55.796 | -84.048 | -49.889 |
| Operating Income Ratio
| -14.601 | -216.709 | -120.402 | -0.675 | 0 | 0 |
| Total Other Income Expenses Net
| 6.404 | 8.766 | 0.826 | 3.384 | 8.743 | 1.104 |
| Income Before Tax
| -341.973 | -290.509 | -363.872 | -52.412 | -75.305 | -48.785 |
| Income Before Tax Ratio
| -13.387 | -210.361 | -120.129 | -0.634 | 0 | 0 |
| Income Tax Expense
| -37.467 | -36.25 | 132.936 | -3.4 | -8.801 | 1.104 |
| Net Income
| -341.973 | -254.259 | -496.808 | -49.012 | -66.504 | -48.785 |
| Net Income Ratio
| -13.387 | -184.112 | -164.017 | -0.593 | 0 | 0 |
| EPS
| -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EPS Diluted
| -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EBITDA
| -380.575 | -322.629 | -89.316 | -52.247 | -81.203 | -46.631 |
| EBITDA Ratio
| -14.898 | -233.62 | -29.487 | -0.632 | 0 | 0 |